Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine

Journal of Infectious Diseases

Volumn 193, Issue 5, 2006, Pages 655-663

  Ovsyannikova, Inna G ^a   Pankratz, V Shane ^a   Vierkant, Robert A ^a   Jacobson, Robert M ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA ANTIGEN; HLA ANTIGEN CLASS 2; HLA DPB1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; LEUKOCYTE ANTIGEN; MEASLES MUMPS RUBELLA VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS ANTIGEN;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; DRUG DESIGN; FEMALE; GENETIC REGULATION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE STATUS; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MEASLES VIRUS; MUMPS VIRUS; NONHUMAN; PRIORITY JOURNAL; RUBELLA VIRUS; SCHOOL CHILD; VACCINATION;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; HAPLOTYPES; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS VIRUS; STATISTICS;

EID: 33244481066     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/500144     Document Type: Article

References (36)

1. Jacobson RM, Poland GA. The genetic basis for measles vaccine failure. Acta Paediatr 2004; 445(Suppl):1-6.
2. Ovsyannikova IG, Jacobson RM, Poland GA. Variation in vaccine response in normal populations. Pharmacogenomics 2004; 5:417-27.
3. Poland GA. Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes. Vaccine 1999; 17:1719-25.
4. Yunis EJ. 1987 Philip Levine award lecture: MHC haplotypes in biology and medicine. Am J Clin Pathol 1988; 89:268-80.
5. Ovsyannikova IG, Jacobson RM, Ryan JE, et al. HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogenetics 2005; 56:798-807.
6. Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol 2004; 65:1506-15.
7. Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. J Infect Dis 2005; 191:515-9.
8. Hill AV. The immunogenetics of human infectious diseases. Annu Rev Immunol 1998; 16:593-617.
9. Newport MJ, Goetghebuer T, Weiss HA, et al. Genetic regulation of immune responses to vaccines in early life. Genes Immun 2004; 5:122-9.
10. So A. Genetics, polymorphism and regulation of expression of HLA region genes. In: Lechler R, ed. HLA and disease. San Diego, CA: Academic Press, 1994:1-29.
11. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004; 39:978-88.
12. Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001; 184:817-26.
13. Jacobson RM, Poland GA, Vierkant RA, et al. The association of class I HLA alleles and antibody levels following a single dose of measles vaccine. Hum Immunol 2003; 64:103-9.
14. Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz SV, Jacobsen SJ, Poland GA. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 2004; 22:1914-20.
15. Pabst HF, Spady DW, Carson MM, Krezolek MP, Barreto L, Wittes RC. Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine 1999; 17:1910-8.
16. Poland GA, Jacobson RM, Colbourne SA, et al. Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine 1999; 17:1525-31.
17. Poland GA, Ovsyannikova IG, Jacobson RM, et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 2001; 20:430-8.
18. Tan PL, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz SV. Twin studies of immunogenicity-determining the genetic contribution to vaccine failure. Vaccine 2001; 19:2434-9.
19. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70:425-34.
20. Tang J, Tang S, Lobashevsky E, et al. Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1. J Virol 2002; 76:8276-84.
21. Bautista-López N, Ward BJ, Mills E, McCormick D, Martel N, Ratnam S. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 2000; 18:1393-401.
22. Ovsyannikova IG, Dhiman N, Jacobson RM, Vierkant RA, Poland GA. Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol 2003; 10:411-6.
23. Gans HA, Maldonado Y, Yasukawa LL, et al. IL-12, IFN-γ, and T cell proliferation to measles in immunized infants. J Immunol 1999; 162:5569-75.
24. Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003; 55:56-65.
25. Dhiman N, Ovsyannikova IG, Jacobson RM, et al. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children. Clin Immunol 2005; 115:154-61.
26. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535-51.
27. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 321:708-12.
28. Craven DE, Awdeh ZL, Kunches LM, et al. Nonresponsiveness to hepatitis B vaccine in health care workers: results of revaccination and genetic typings. Ann Intern Med 1986; 105:356-60.
29. Kruskall MS. The major histocompatibility complex: the value of extended haplotypes in the analysis of associated immune diseases and disorders. Yale J Biol Med 1990; 63:477-86.
30. Hatae K, Kimura A, Okubo R, et al. Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype. Eur J Immunol 1992; 22:1899-905.
31. Li M, Li R, Huang S, et al. The relationship between nonresponse to hepatitis B vaccine and HLA genotype/haplotype. Zhonghua Yu Fang Yi Xue Za Zhi (Chinese Journal of Preventive Medicine) 2002; 36:180-3.
32. Clark AG. The role of haplotypes in candidate gene studies. Genet Epidemiol 2004; 27:321-33.
33. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-11.
34. Mellins E, Woelfel M, Pious D. Importance of HLA-DQ and -DP restriction elements in T-cell responses to soluble antigens: mutational analysis. Hum Immunol 1987; 18:211-23.
35. Sierpe EAG, Keller E, Bettinotti MDLP, et al. Oligotyping with DRB generic amplified DNA and oligonucleotides 0-25. In: Tsuji K, Aizawa M, Sasazuki T, eds. HLA 1991: Proceedings of the Eleventh International Histocompatibility Workshop and Conference. Oxford: Oxford University Press, 1992:454-7.
36. Alper CA, Awdeh Z, Yunis EJ. Conserved, extended MHC haplotypes. Exp Clin Immunogenet 1992; 9:58-71.